Weight Loss— The Preferred Treatment for NASH

Time: 9:00 am
day: Day One


• Bariatric and epidemiologic studies provide compelling evidence that weight loss is the preferred treatment option for NASH and its co-morbidities
• GLP-1 based agents and dual agonists have achieved sufficient weight loss in clinical trials to drive potent reductions in liver fat reduction and NASH inflammation, but further evidence is needed to demonstrate meaningful effects on NASH fibrosis
• Tolerability due to GI side effects remains a barrier to the use of GLP-1 based agents